Abstract:Duchenne muscular dystrophy is life-limiting. Cardiomyopathy, which mostly ensues in the second decade of life, is the main cause of death. Treatment options are still limited. The TAMDMD (NCT03354039) trial assessed motor function, muscle strength and structure, laboratory biomarkers, and safety in 79 ambulant boys with genetically confirmed Duchenne muscular dystrophy, 6.5-12 years of age, receiving either daily tamoxifen 20 mg or placebo for 48 weeks. In this post-hoc analysis, available echocardiographic data of ambulant patients recruited at one study centre were retrieved and compared before and after treatment. Data from 14 patients, median 11 (interquartile range, IQR, 11-12) years of age was available. Baseline demographic characteristics were similar in participants assigned to placebo (n = 7) or tamoxifen (n = 7). Left ventricular end-diastolic diameter in the placebo group (median and IQR) was 39 (38-41) mm at baseline and 43 (38-44) mm at study end, while it was 44 (41-46) mm at baseline and 41 (37-46) mm after treatment in the tamoxifen group. Left ventricular fractional shortening in the placebo group was 35% (32-38%) before and 33% (32-36%) after treatment, while in the tamoxifen group it was 34% (33-34%) at baseline and 35% (33-35%) at study end. No safety signals were detected. Conclusion: This hypothesis-generating post-hoc analysis suggests that tamoxifen over 48 weeks is well tolerated and may help preserving cardiac structure and function in Duchenne muscular dystrophy. Further studies are justified. Clinicaltrials: gov Identifier: EudraCT 2017-004554-42, NCT03354039 What is known: • Duchenne muscular dystrophy (DMD) is life-limiting. Cardiomyopathy ensues in the second decade of life and is the main cause of death. Treatment options are still limited. • Tamoxifen reduced cardiac fibrosis in mice and improved cardiomyocyte function in human-induced pluripotent stem cell-derived cardiomyocytes. What is new: • In this post-hoc analysis of the TAMDMD trial among 14 boys, median 11 years of age, treated with either tamoxifen or placebo for 48 weeks, treatment was well-tolerated. • A visual trend of improved left-ventricular dimensions and better systolic function preservation generates the hypothesis of a potential beneficial effect of tamoxifen in DMD cardiomyopathy.

Tamoxifen Treatment Ameliorates Contractile Dysfunction of Duchenne Muscular Dystrophy Stem Cell-Derived Cardiomyocytes on Bioengineered Substrates.

Tamoxifen may contribute to preserve cardiac function in Duchenne muscular dystrophy

Functional and Pathological Improvements of the Hearts in Diabetes Model by the Combined Therapy of Bfgf-Loaded Nanoparticles with Ultrasound-Targeted Microbubble Destruction.

Prevent Diabetic Cardiomyopathy in Diabetic Rats by Combined Therapy of Afgf-Loaded Nanoparticles and Ultrasound-Targeted Microbubble Destruction Technique.

Increased Tissue Stiffness Triggers Contractile Dysfunction and Telomere Shortening in Dystrophic Cardiomyocytes.

Abstract 211: Substrate Elasticity Impacts Duchenne Muscular Dystrophy Cardiomyopathy Progression

Abstract 310: Mechanistic Insights into Duchenne Muscular Dystrophy-Associated Cardiomyopathy

Functional cardiac consequences of β-adrenergic stress-induced injury in a model of Duchenne muscular dystrophy

Abstract 477: Role of Telomere Dysfunction in Duchenne Muscular Dystrophy Cardiomyopathy

Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin-Deficient D2.B10-Dmd mdx /J Mouse

TRF2 rescues telomere attrition and prolongs cell survival in Duchenne muscular dystrophy cardiomyocytes derived from human iPSCs

A state-of-the-art review of tamoxifen as a potential therapeutic for duchenne muscular dystrophy

Using Basic Fibroblast Growth Factor Nanoliposome Combined With Ultrasound-Introduced Technology To Early Intervene The Diabetic Cardiomyopathy

Cardioprotection and Suppression of Fibrosis by Diverse Cancer and Non-Cancer Cell Lines in a Murine Model of Duchenne Muscular Dystrophy

Targeting of CAT and VCAM1 As Novel Therapeutic Targets for DMD Cardiomyopathy

Functional cardiac consequences of β-adrenergic stress-induced injury in the mouse model of Duchenne muscular dystrophy

Advanced Interfere Treatment of Diabetic Cardiomyopathy Rats by Afgf-Loaded Heparin-Modified Microbubbles and UTMD Technique

Adiponectin-receptor agonism prevents right ventricular tissue pathology in a mouse model of Duchenne muscular dystrophy

Recombinant annexin A6 promotes membrane repair in a stem cell derived-cardiomyocyte model of dystrophic cardiomyopathy

Cardiomyopathy in Duchenne Muscular Dystrophy and the Potential for Mitochondrial Therapeutics to Improve Treatment Response

Disrupted cardiac bioenergetics linked to oxidized mitochondrial creatine kinase are rescued by the mitochondrial-targeting peptide SBT-20 in the D2.mdx model of Duchenne muscular dystrophy